S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$6.15
-2.8%
$5.93
$5.26
$11.38
$246.37M0.66576,920 shs258,980 shs
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$25.50
-0.7%
$25.20
$16.54
$28.58
$378.68M0.7681,557 shs41,079 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$26.39
-0.5%
$29.65
$16.79
$39.41
$375.79M1.0156,367 shs21,613 shs
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$1.36
$1.22
$0.75
$7.44
$8.43M-1.113,980 shs435 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-2.76%-7.59%+17.44%+8.39%-27.90%
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
+0.71%-0.66%+1.66%+14.43%-7.66%
Surmodics, Inc. stock logo
SRDX
Surmodics
-0.30%-4.05%-3.46%-22.25%+14.85%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00%-4.23%+0.74%+33.01%-67.41%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
4.483 of 5 stars
3.54.00.04.22.73.30.6
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
2.7346 of 5 stars
2.31.00.03.60.61.71.9
Surmodics, Inc. stock logo
SRDX
Surmodics
4.147 of 5 stars
3.52.00.03.42.41.71.9
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
3.00
Buy$14.25131.71% Upside
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
2.50
Moderate Buy$29.5015.69% Upside
Surmodics, Inc. stock logo
SRDX
Surmodics
3.00
Buy$59.00123.57% Upside
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/A

Current Analyst Ratings

Latest ANIK, VAPO, ANGO, and SRDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00
4/5/2024
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$12.00
3/14/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$22.00
3/14/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$29.00 ➝ $37.00
2/1/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$44.00 ➝ $47.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$338.75M0.73$1.04 per share5.94$5.46 per share1.13
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$166.66M2.27$4.92 per share5.18$14.50 per share1.76
Surmodics, Inc. stock logo
SRDX
Surmodics
$132.58M2.83$0.78 per share33.92$8.48 per share3.11
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$68.67M0.12N/AN/A($9.01) per share-0.15

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$52.44M-$4.84N/AN/AN/A-60.21%-3.48%-2.68%7/10/2024 (Estimated)
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$82.67M-$5.65N/A18.892.28-49.60%-2.10%-1.71%5/14/2024 (Estimated)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$1.54M$0.3869.45N/AN/A3.99%8.06%5.11%4/24/2024 (Estimated)
Vapotherm, Inc. stock logo
VAPO
Vapotherm
-$58.19M-$9.90N/AN/A-84.74%N/A-65.84%5/1/2024 (Estimated)

Latest ANIK, VAPO, ANGO, and SRDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/13/2024Q4 2023
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$0.15$0.05+$0.20$4.40$41.51 million$42.97 million
2/22/2024Q4 2023
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A-$1.60-$1.60-$1.60N/A$19.73 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/AN/AN/AN/AN/A
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/A
2.29
1.62
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.26
3.76
Surmodics, Inc. stock logo
SRDX
Surmodics
0.24
4.84
3.97
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A
2.43
1.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
89.43%
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
91.53%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
43.08%

Insider Ownership

CompanyInsider Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
5.10%
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
5.85%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
15.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
81540.06 million38.01 millionOptionable
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
35714.85 million13.98 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
37614.24 million12.97 millionOptionable
Vapotherm, Inc. stock logo
VAPO
Vapotherm
1826.20 million5.22 millionOptionable

ANIK, VAPO, ANGO, and SRDX Headlines

SourceHeadline
Onymos Powers Connected Cloud App for Global Medical Technology Company, VapothermOnymos Powers Connected Cloud App for Global Medical Technology Company, Vapotherm
dbta.com - March 25 at 5:37 PM
Vapotherm to debut home ventilator to improve patient careVapotherm to debut home ventilator to improve patient care
msn.com - March 20 at 7:36 PM
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
finance.yahoo.com - March 20 at 7:36 PM
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADEVapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
finance.yahoo.com - March 15 at 10:23 AM
Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherms High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfortDr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort
prnewswire.com - March 6 at 6:45 AM
Vapotherms HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South Americas Largest Health Care MarketVapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market
prnewswire.com - February 29 at 6:45 AM
Vapotherm, Inc.: Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsVapotherm, Inc.: Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - February 23 at 7:30 AM
Vapotherm: Q4 Earnings SnapshotVapotherm: Q4 Earnings Snapshot
chron.com - February 22 at 9:28 PM
Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsVapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
prnewswire.com - February 22 at 4:10 PM
Innovations Shaping The Future Of Standalone High Flow Oxygen Therapy Devices Market DynamicsInnovations Shaping The Future Of Standalone High Flow Oxygen Therapy Devices Market Dynamics
opprairie.com - February 12 at 10:06 AM
Vapotherm: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Financial Statements And ExhibitsVapotherm: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Financial Statements And Exhibits
cbonds.com - December 17 at 8:45 AM
OTC Markets Group Welcomes Vapotherm, Inc. to OTCQXOTC Markets Group Welcomes Vapotherm, Inc. to OTCQX
financialpost.com - December 15 at 7:08 AM
NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO)
finance.yahoo.com - December 14 at 8:20 PM
Vapotherm Shares Suspended on NYSE, Company Previously Announced Voluntary Delisting PlanVapotherm Shares Suspended on NYSE, Company Previously Announced Voluntary Delisting Plan
marketwatch.com - December 14 at 8:20 PM
Vapotherm Shares Decline 22% on Voluntary Delisting Grom NYSEVapotherm Shares Decline 22% on Voluntary Delisting Grom NYSE
marketwatch.com - December 11 at 1:11 PM
Vapotherm slips on announcing voluntary delisting from NYSE to OTCQX MarketplaceVapotherm slips on announcing voluntary delisting from NYSE to OTCQX Marketplace
msn.com - December 11 at 8:11 AM
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQXVapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX
finance.yahoo.com - December 11 at 8:11 AM
Vapotherm Educates over 8,000 Clinicians in Respiratory Care MonthVapotherm Educates over 8,000 Clinicians in Respiratory Care Month
finance.yahoo.com - November 28 at 8:21 PM
Vapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call TranscriptVapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 10 at 2:28 PM
Vapotherm GAAP EPS of -$2.38 misses by $0.18, revenue of $15.2M misses by $1.52MVapotherm GAAP EPS of -$2.38 misses by $0.18, revenue of $15.2M misses by $1.52M
msn.com - November 8 at 7:38 PM
Vapotherm Reports Third Quarter 2023 Financial ResultsVapotherm Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 8 at 7:38 PM
Vapotherm, Inc. (VAPO) stock price, news, quote & history – Yahoo FinanceVapotherm, Inc. (VAPO) stock price, news, quote & history – Yahoo Finance
uk.finance.yahoo.com - November 8 at 9:36 AM
Earnings Outlook For VapothermEarnings Outlook For Vapotherm
benzinga.com - November 7 at 6:13 PM
Vapotherm To Report Third Quarter 2023 Financial ResultsVapotherm To Report Third Quarter 2023 Financial Results
finance.yahoo.com - November 1 at 8:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AngioDynamics logo

AngioDynamics

NASDAQ:ANGO
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Anika Therapeutics logo

Anika Therapeutics

NASDAQ:ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Surmodics logo

Surmodics

NASDAQ:SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Vapotherm logo

Vapotherm

NYSE:VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.